Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05930561 · ClinicalTrials.gov registry record · Phase 2
4D-150 in Patients With Diabetic Macular Edema
A Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by 4D Molecular Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 6
- Study locations
NCT05930561 is a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy that is active but no longer recruiting, run by 4D Molecular Therapeutics. The registered enrollment target is 72 participants, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT05930561, a Phase 2 study of Diabetic Macular Edema and Diabetic Retinopathy, is active but no longer recruiting, sponsored by 4D Molecular Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Conditions Studied
Interventions
- BIOLOGICAL 4D-150 IVT
- BIOLOGICAL Aflibercept IVT
Study Locations (6)
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Oregon
- Verum Research, LLC - Eugene
Pennsylvania
- Erie Retina Research - Erie
Texas
- Austin Clinical Research - Austin
Virginia
- Piedmont Eye Center - Lynchburg
Other
- Emanuelli Research and Development Center - Arecibo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-08-09 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05930561
The ClinicalTrials.gov registry entry for NCT05930561 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,793-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (98% lower). The listed sponsor is 4D Molecular Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which 4D-150 IVT is the first listed.
NCT05930561 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Maryland, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05930561 about?
NCT05930561 is a clinical study titled "4D-150 in Patients With Diabetic Macular Edema". Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
What is the current status of trial NCT05930561?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2023-08-09. Estimated completion is 2029-02-28.
What conditions does trial NCT05930561 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy.
What interventions are being tested in trial NCT05930561?
The interventions under investigation include: 4D-150 IVT (BIOLOGICAL), Aflibercept IVT (BIOLOGICAL).
Who is sponsoring clinical trial NCT05930561?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05930561 being conducted?
This trial has 6 study locations across Maryland, Oregon, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
RECRUITING · Phase 2
-
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Tonabersat for DME
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
COMPLETED · Phase 2
-
Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.